Brief: Liminal Announces Resubmission Of Biologics License Application To U.S. FDA For Ryplazim

Liminal BioSciences

08/09/2020 11:58

Sept 8 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * LIMINAL BIOSCIENCES ANNOUNCES RESUBMISSION OF BIOLOGICS
LICENSE
APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR RYPLAZIM®
(PLASMINOGEN) FOR TREATMENT OF CONGENITAL PLASMINOGEN DEFICIENCY
    * LIMINAL BIOSCIENCES INC - RESULTS FROM PIVOTAL PHASE 2/3
STUDY
MET CO-PRIMARY ENDPOINTS
    * LIMINAL - BELIEVES AMENDED BLA REPRESENTS A CLASS 2
RESUBMISSION
THAT WOULD PROVIDE FOR PDUFA DATE WITHIN 6 MONTHS FROM DATE OF
RESUBMISSION

Source text for Eikon:  ID:nCNWpB2hNa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))